The overall goal of the proposed study is the discovery and preclinical validation of novel targets associated with molecular processes that lead to cognitive decline, the primary outcome of most AD trials. The recent NIA Alzheimer's Disease Research Summit 2012: Path to Treatment and Prevention that led to the RFA to which we are responding, made a number of recommendations which motivated the strategy adopted in the proposed study. Our proposal brings together an exceptionally strong and unique multi-disciplinary team with the relevant skills needed to achieve our overall goal.
In Aim 1, we take a systems biology approach to mine a truly unique set of deep clinical, paraclinical, pathologic, genomic, epigenomic, and transcriptomic data assembled from frozen dorsolateral prefrontal cortex brain tissue of 1000 subjects from two cohort studies of aging and dementia, the Religious Order Study and the Memory and Aging Project, in conjunction with other publicly available functional datasets. These unique data provide an excellent substrate for the identification and nomination of molecular targets for drug discovery. Target discovery is coupled with a flexible translational strategy that first validates targets by a targeted proteomic study of brain tissue from the same region and subjects in Aim 2.
In Aim 3, an RNA interference (RNAi) and overexpression functional validation study in cultured human neurons and astrocytes is executed in parallel in Aim 3. Finally, these data come together in Aim 4 which performs high throughput small molecule screens on neurons and astrocytes derived from induced pluripotent stem cells (iPSC) on the most promising targets. Our proposal is ambitious but realistic: it reflects the deployment of cutting-edge approaches with a practical mindset in which redundancies have been carefully considered to mitigate risk and ensure the delivery of data, network models and lead compounds. The proposed study will discover and validate novel targets associated with molecular processes that lead to cognitive decline, and it will demonstrate the druggability of one or more targets, setting the stage for clinical trials with new and novel approaches to the prevention and treatment of AD.

Public Health Relevance

The prevention and treatment of AD is a major public health priority. However, novel therapeutic targets are urgently needed. The proposed study will leverage deep phenotypic and multi-level -omics data to identify novel therapeutic targets, functionally validate and subsequently demonstrate the druggability of a number of selected targets, thereby filling an important gap between the new generation of -omics technology and the identification of novel and druggable targets to move to preclinical or clinical trials.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project--Cooperative Agreements (U01)
Project #
1U01AG046152-01
Application #
8605315
Study Section
Special Emphasis Panel (ZAG1-ZIJ-6 (A1))
Program Officer
Petanceska, Suzana
Project Start
2013-09-20
Project End
2018-08-31
Budget Start
2013-09-20
Budget End
2014-08-31
Support Year
1
Fiscal Year
2013
Total Cost
$1,694,201
Indirect Cost
$229,589
Name
Broad Institute, Inc.
Department
Type
DUNS #
623544785
City
Cambridge
State
MA
Country
United States
Zip Code
02142
Do Carmo, Sonia; Hanzel, Cecilia E; Jacobs, Marie L et al. (2016) Rescue of Early bace-1 and Global DNA Demethylation by S-Adenosylmethionine Reduces Amyloid Pathology and Improves Cognition in an Alzheimer's Model. Sci Rep 6:34051
Hohman, Timothy J; Bush, William S; Jiang, Lan et al. (2016) Discovery of gene-gene interactions across multiple independent data sets of late onset Alzheimer disease from the Alzheimer Disease Genetics Consortium. Neurobiol Aging 38:141-50
Farfel, Jose M; Yu, Lei; De Jager, Philip L et al. (2016) Association of APOE with tau-tangle pathology with and without β-amyloid. Neurobiol Aging 37:19-25
Yu, Lei; Chibnik, Lori B; Yang, Jingyun et al. (2016) Methylation profiles in peripheral blood CD4+ lymphocytes versus brain: The relation to Alzheimer's disease pathology. Alzheimers Dement 12:942-51
Gaiteri, Chris; Mostafavi, Sara; Honey, Christopher J et al. (2016) Genetic variants in Alzheimer disease - molecular and brain network approaches. Nat Rev Neurol 12:413-27
Yu, Lei; De Jager, Philip L; Yang, Jingyun et al. (2015) The TMEM106B locus and TDP-43 pathology in older persons without FTLD. Neurology 84:927-34
Yang, Jingyun; Yu, Lei; Gaiteri, Christopher et al. (2015) Association of DNA methylation in the brain with age in older persons is confounded by common neuropathologies. Int J Biochem Cell Biol 67:58-64
Bennett, David A; Yu, Lei; Yang, Jingyun et al. (2015) Epigenomics of Alzheimer's disease. Transl Res 165:200-20
Replogle, Joseph M; Chan, Gail; White, Charles C et al. (2015) A TREM1 variant alters the accumulation of Alzheimer-related amyloid pathology. Ann Neurol 77:469-77
Yu, Lei; Chibnik, Lori B; Srivastava, Gyan P et al. (2015) Association of Brain DNA methylation in SORL1, ABCA7, HLA-DRB5, SLC24A4, and BIN1 with pathological diagnosis of Alzheimer disease. JAMA Neurol 72:15-24

Showing the most recent 10 out of 20 publications